Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1

Interventions

Vorinostat 3Azacitidine 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2durvalumab 2dabrafenib 2copanlisib 2aflibercept 2abiraterone 2Sunitinib 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Dasatinib 2Cyclophosphamide 2Biopsy 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × gallium maltolate × Lymphoid × Clear all
NCT00050687 2011-01-28

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Titan Pharmaceuticals

Phase 1/2 Terminated
GenitourinaryLymphoidPlasma cell

Urinary Bladder Neoplasms, Lymphoma, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡